| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Research Design | 27 | 2024 | 1544 | 7.570 |
Why?
|
| Bayes Theorem | 39 | 2024 | 1021 | 7.280 |
Why?
|
| Clinical Trials, Phase I as Topic | 12 | 2022 | 604 | 4.440 |
Why?
|
| Clinical Trials, Phase II as Topic | 11 | 2023 | 665 | 3.880 |
Why?
|
| Models, Statistical | 24 | 2021 | 1171 | 3.750 |
Why?
|
| Computer Simulation | 38 | 2024 | 1529 | 3.280 |
Why?
|
| Maximum Tolerated Dose | 16 | 2022 | 1290 | 2.720 |
Why?
|
| Biometry | 9 | 2019 | 241 | 2.630 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2022 | 4938 | 2.390 |
Why?
|
| Sample Size | 14 | 2023 | 202 | 2.180 |
Why?
|
| Data Interpretation, Statistical | 8 | 2020 | 482 | 1.640 |
Why?
|
| Software | 5 | 2021 | 1321 | 1.530 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2023 | 2594 | 1.280 |
Why?
|
| Algorithms | 16 | 2020 | 3890 | 1.230 |
Why?
|
| Medical Oncology | 4 | 2022 | 1423 | 1.090 |
Why?
|
| Immunotherapy | 8 | 2023 | 3341 | 1.070 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 152 | 1.000 |
Why?
|
| Clinical Trials as Topic | 10 | 2023 | 3719 | 0.980 |
Why?
|
| Endpoint Determination | 5 | 2020 | 176 | 0.930 |
Why?
|
| Drug Overdose | 1 | 2022 | 81 | 0.840 |
Why?
|
| Psychology | 2 | 2013 | 86 | 0.810 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2019 | 3 | 0.720 |
Why?
|
| Drug Therapy, Computer-Assisted | 2 | 2011 | 46 | 0.700 |
Why?
|
| Epidemiologic Research Design | 2 | 2009 | 11 | 0.680 |
Why?
|
| Humans | 112 | 2024 | 261506 | 0.670 |
Why?
|
| Neoplasms | 19 | 2024 | 15193 | 0.670 |
Why?
|
| Molecular Targeted Therapy | 4 | 2024 | 2330 | 0.630 |
Why?
|
| Antineoplastic Agents | 15 | 2022 | 14289 | 0.580 |
Why?
|
| Models, Biological | 4 | 2012 | 3254 | 0.560 |
Why?
|
| Brain Neoplasms | 13 | 2024 | 4849 | 0.530 |
Why?
|
| E2F1 Transcription Factor | 1 | 2016 | 206 | 0.530 |
Why?
|
| Glioblastoma | 8 | 2020 | 1797 | 0.520 |
Why?
|
| Decision Making | 1 | 2023 | 1287 | 0.510 |
Why?
|
| Statistics as Topic | 2 | 2013 | 445 | 0.490 |
Why?
|
| Patient Compliance | 3 | 2017 | 667 | 0.490 |
Why?
|
| Erectile Dysfunction | 2 | 2013 | 212 | 0.490 |
Why?
|
| Glioma | 8 | 2024 | 1963 | 0.480 |
Why?
|
| Endometrial Neoplasms | 7 | 2021 | 1341 | 0.470 |
Why?
|
| Pharmacogenetics | 1 | 2015 | 260 | 0.460 |
Why?
|
| Patient Dropouts | 1 | 2013 | 88 | 0.450 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2023 | 598 | 0.450 |
Why?
|
| Probability | 5 | 2023 | 866 | 0.450 |
Why?
|
| Oncolytic Viruses | 3 | 2021 | 204 | 0.440 |
Why?
|
| Bias | 4 | 2017 | 205 | 0.440 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 1084 | 0.440 |
Why?
|
| Regression Analysis | 4 | 2013 | 1546 | 0.420 |
Why?
|
| Oncolytic Virotherapy | 3 | 2021 | 280 | 0.420 |
Why?
|
| Toxicity Tests | 1 | 2011 | 50 | 0.400 |
Why?
|
| Pancreatic Neoplasms | 3 | 2024 | 5061 | 0.380 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2016 | 1105 | 0.370 |
Why?
|
| Meta-Analysis as Topic | 2 | 2008 | 276 | 0.370 |
Why?
|
| Biomarkers | 8 | 2022 | 5047 | 0.360 |
Why?
|
| Colorectal Neoplasms | 7 | 2024 | 3578 | 0.360 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 2315 | 0.350 |
Why?
|
| Ovarian Neoplasms | 6 | 2024 | 4638 | 0.350 |
Why?
|
| Models, Genetic | 1 | 2013 | 1113 | 0.340 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 32 | 0.330 |
Why?
|
| Models, Psychological | 1 | 2009 | 170 | 0.330 |
Why?
|
| Flavones | 2 | 2018 | 15 | 0.330 |
Why?
|
| Information Storage and Retrieval | 1 | 2009 | 135 | 0.320 |
Why?
|
| Longitudinal Studies | 2 | 2013 | 1945 | 0.310 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 980 | 0.310 |
Why?
|
| Metformin | 2 | 2024 | 378 | 0.300 |
Why?
|
| Cluster Analysis | 3 | 2015 | 1053 | 0.300 |
Why?
|
| Demography | 2 | 2007 | 435 | 0.280 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 15862 | 0.280 |
Why?
|
| Risk Assessment | 3 | 2009 | 6869 | 0.280 |
Why?
|
| Pattern Recognition, Automated | 3 | 2013 | 125 | 0.270 |
Why?
|
| Head and Neck Neoplasms | 5 | 2022 | 3976 | 0.270 |
Why?
|
| Logistic Models | 4 | 2022 | 3441 | 0.270 |
Why?
|
| Venous Thromboembolism | 2 | 2024 | 335 | 0.260 |
Why?
|
| Reproducibility of Results | 7 | 2021 | 6009 | 0.260 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2020 | 323 | 0.260 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2022 | 5437 | 0.260 |
Why?
|
| Drug Administration Schedule | 4 | 2021 | 3472 | 0.250 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 4549 | 0.250 |
Why?
|
| Benzofurans | 1 | 2024 | 38 | 0.240 |
Why?
|
| Treatment Outcome | 16 | 2021 | 32848 | 0.240 |
Why?
|
| Benzoxazoles | 1 | 2024 | 41 | 0.230 |
Why?
|
| MicroRNAs | 1 | 2016 | 2947 | 0.220 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2024 | 1724 | 0.220 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2023 | 447 | 0.210 |
Why?
|
| Leiomyosarcoma | 1 | 2024 | 223 | 0.210 |
Why?
|
| DNA Polymerase II | 1 | 2022 | 59 | 0.210 |
Why?
|
| Sensitivity and Specificity | 8 | 2015 | 4971 | 0.210 |
Why?
|
| Morpholines | 2 | 2015 | 289 | 0.200 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2022 | 109 | 0.200 |
Why?
|
| Female | 45 | 2024 | 141928 | 0.200 |
Why?
|
| Exanthema | 1 | 2024 | 211 | 0.200 |
Why?
|
| Aminopyridines | 2 | 2015 | 212 | 0.200 |
Why?
|
| Text Messaging | 1 | 2021 | 35 | 0.200 |
Why?
|
| Early Detection of Cancer | 3 | 2017 | 1258 | 0.200 |
Why?
|
| Adenine | 1 | 2024 | 631 | 0.190 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2013 | 129 | 0.190 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2020 | 32 | 0.190 |
Why?
|
| Spouses | 1 | 2021 | 134 | 0.190 |
Why?
|
| Body Image | 2 | 2012 | 141 | 0.190 |
Why?
|
| Tobacco Products | 1 | 2021 | 120 | 0.190 |
Why?
|
| Levonorgestrel | 1 | 2020 | 49 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 4367 | 0.180 |
Why?
|
| Premenopause | 1 | 2020 | 131 | 0.180 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2024 | 413 | 0.180 |
Why?
|
| Biostatistics | 1 | 2019 | 20 | 0.180 |
Why?
|
| Middle Aged | 31 | 2024 | 86204 | 0.180 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 402 | 0.180 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2019 | 32 | 0.180 |
Why?
|
| Research Support as Topic | 1 | 2020 | 122 | 0.180 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2019 | 182 | 0.180 |
Why?
|
| Endometrial Hyperplasia | 1 | 2020 | 112 | 0.180 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 5767 | 0.170 |
Why?
|
| Everolimus | 1 | 2021 | 415 | 0.170 |
Why?
|
| Adult | 27 | 2020 | 77950 | 0.160 |
Why?
|
| Adenylate Kinase | 1 | 2018 | 36 | 0.160 |
Why?
|
| Male | 32 | 2024 | 123000 | 0.160 |
Why?
|
| Life Style | 1 | 2021 | 612 | 0.160 |
Why?
|
| Case-Control Studies | 4 | 2016 | 6100 | 0.160 |
Why?
|
| Aged | 25 | 2023 | 70117 | 0.160 |
Why?
|
| Healthy Lifestyle | 1 | 2018 | 44 | 0.160 |
Why?
|
| Internet | 2 | 2013 | 706 | 0.160 |
Why?
|
| Chemokine CXCL1 | 1 | 2017 | 60 | 0.150 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 11538 | 0.150 |
Why?
|
| Therapies, Investigational | 1 | 2018 | 62 | 0.150 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2021 | 607 | 0.150 |
Why?
|
| Diet, Cariogenic | 2 | 2007 | 2 | 0.150 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 669 | 0.150 |
Why?
|
| Weight Reduction Programs | 1 | 2018 | 78 | 0.150 |
Why?
|
| Health Behavior | 1 | 2021 | 603 | 0.150 |
Why?
|
| Dental Caries | 2 | 2007 | 22 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 3 | 2015 | 1443 | 0.150 |
Why?
|
| PPAR gamma | 1 | 2018 | 229 | 0.150 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2018 | 204 | 0.150 |
Why?
|
| Obesity | 2 | 2020 | 2884 | 0.140 |
Why?
|
| Thrombocytosis | 1 | 2017 | 121 | 0.140 |
Why?
|
| Estrogens | 1 | 2020 | 751 | 0.140 |
Why?
|
| Area Under Curve | 2 | 2015 | 700 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2018 | 467 | 0.140 |
Why?
|
| Polycomb-Group Proteins | 1 | 2015 | 42 | 0.140 |
Why?
|
| Time Factors | 5 | 2018 | 12926 | 0.140 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2017 | 292 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2024 | 1390 | 0.140 |
Why?
|
| Rectal Neoplasms | 1 | 2024 | 1202 | 0.130 |
Why?
|
| ROC Curve | 2 | 2018 | 1183 | 0.130 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 343 | 0.130 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2018 | 833 | 0.130 |
Why?
|
| CD4-CD8 Ratio | 1 | 2015 | 58 | 0.130 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2015 | 85 | 0.130 |
Why?
|
| DNA Mismatch Repair | 1 | 2017 | 268 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 5319 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 3251 | 0.130 |
Why?
|
| Prognosis | 7 | 2020 | 21713 | 0.130 |
Why?
|
| Human papillomavirus 16 | 1 | 2016 | 256 | 0.130 |
Why?
|
| Microsatellite Instability | 1 | 2017 | 400 | 0.130 |
Why?
|
| Liver Neoplasms | 3 | 2022 | 4557 | 0.130 |
Why?
|
| Cancer Survivors | 1 | 2021 | 650 | 0.130 |
Why?
|
| Cancer Care Facilities | 1 | 2019 | 884 | 0.120 |
Why?
|
| Mitotic Index | 1 | 2015 | 162 | 0.120 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2015 | 157 | 0.120 |
Why?
|
| Survivors | 2 | 2011 | 1031 | 0.120 |
Why?
|
| Likelihood Functions | 1 | 2015 | 233 | 0.120 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2015 | 297 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2019 | 6207 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 4298 | 0.120 |
Why?
|
| Apoptosis | 4 | 2018 | 7591 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2023 | 1330 | 0.120 |
Why?
|
| Linkage Disequilibrium | 2 | 2013 | 460 | 0.120 |
Why?
|
| Esophagogastric Junction | 1 | 2018 | 543 | 0.120 |
Why?
|
| Social Sciences | 1 | 2013 | 5 | 0.120 |
Why?
|
| Respiratory-Gated Imaging Techniques | 1 | 2014 | 51 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 848 | 0.120 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 66 | 0.120 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2015 | 197 | 0.120 |
Why?
|
| Gene Expression Profiling | 3 | 2015 | 5159 | 0.120 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 4654 | 0.120 |
Why?
|
| Diet | 1 | 2021 | 1440 | 0.120 |
Why?
|
| Ganglioglioma | 1 | 2013 | 41 | 0.120 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2014 | 99 | 0.120 |
Why?
|
| Kidney Neoplasms | 2 | 2022 | 3022 | 0.110 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 216 | 0.110 |
Why?
|
| Quality of Life | 5 | 2020 | 4532 | 0.110 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2013 | 31 | 0.110 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2014 | 142 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 1 | 2015 | 543 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2018 | 925 | 0.110 |
Why?
|
| Stomach Neoplasms | 3 | 2018 | 2278 | 0.110 |
Why?
|
| Family | 1 | 2017 | 736 | 0.110 |
Why?
|
| Supratentorial Neoplasms | 1 | 2013 | 78 | 0.110 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2017 | 469 | 0.110 |
Why?
|
| Oncogenes | 1 | 2016 | 673 | 0.110 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 29902 | 0.110 |
Why?
|
| Cell Line, Tumor | 9 | 2021 | 14551 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 1350 | 0.110 |
Why?
|
| Young Adult | 12 | 2021 | 21445 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2015 | 362 | 0.110 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2015 | 461 | 0.110 |
Why?
|
| Deglutition | 1 | 2013 | 171 | 0.110 |
Why?
|
| Neoplasm Staging | 8 | 2021 | 13658 | 0.110 |
Why?
|
| Binding Sites | 1 | 2016 | 2171 | 0.110 |
Why?
|
| Tumor Microenvironment | 5 | 2022 | 2864 | 0.110 |
Why?
|
| Pilot Projects | 4 | 2021 | 2803 | 0.110 |
Why?
|
| Ependymoma | 1 | 2014 | 242 | 0.100 |
Why?
|
| Inflammatory Breast Neoplasms | 1 | 2017 | 509 | 0.100 |
Why?
|
| Couples Therapy | 1 | 2011 | 3 | 0.100 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 222 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 10035 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 551 | 0.100 |
Why?
|
| Sex Counseling | 1 | 2011 | 16 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2018 | 1226 | 0.100 |
Why?
|
| Mice, Nude | 5 | 2018 | 4307 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2013 | 196 | 0.100 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2024 | 265 | 0.100 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 1215 | 0.100 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 697 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2022 | 7702 | 0.100 |
Why?
|
| Epidemiologic Methods | 2 | 2009 | 254 | 0.100 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2014 | 361 | 0.100 |
Why?
|
| Self-Help Groups | 1 | 2011 | 37 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 6915 | 0.100 |
Why?
|
| Markov Chains | 1 | 2011 | 175 | 0.100 |
Why?
|
| Artifacts | 1 | 2014 | 532 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 503 | 0.100 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2015 | 480 | 0.100 |
Why?
|
| Feeding Behavior | 2 | 2007 | 808 | 0.090 |
Why?
|
| Exercise Therapy | 1 | 2013 | 288 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2014 | 383 | 0.090 |
Why?
|
| Pyridones | 1 | 2013 | 348 | 0.090 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 7789 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 1323 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 778 | 0.090 |
Why?
|
| Animals | 13 | 2021 | 59536 | 0.090 |
Why?
|
| Disease-Free Survival | 5 | 2014 | 10001 | 0.090 |
Why?
|
| RNA, Long Noncoding | 1 | 2015 | 598 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 592 | 0.090 |
Why?
|
| Carbonated Beverages | 2 | 2007 | 11 | 0.090 |
Why?
|
| Disclosure | 1 | 2011 | 181 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 2326 | 0.090 |
Why?
|
| Deglutition Disorders | 1 | 2013 | 447 | 0.090 |
Why?
|
| Signal Transduction | 5 | 2021 | 11965 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1516 | 0.090 |
Why?
|
| Smoking Cessation | 1 | 2015 | 712 | 0.090 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 622 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2024 | 1678 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 3821 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2018 | 2027 | 0.080 |
Why?
|
| Genes, BRCA2 | 1 | 2011 | 309 | 0.080 |
Why?
|
| Linear Models | 2 | 2009 | 1085 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 1121 | 0.080 |
Why?
|
| Genes, BRCA1 | 1 | 2011 | 387 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2009 | 756 | 0.080 |
Why?
|
| Lymphangiogenesis | 1 | 2008 | 46 | 0.080 |
Why?
|
| Dietary Carbohydrates | 1 | 2007 | 134 | 0.070 |
Why?
|
| Immunomodulation | 2 | 2019 | 242 | 0.070 |
Why?
|
| Prostatectomy | 1 | 2011 | 962 | 0.070 |
Why?
|
| Breast Neoplasms | 4 | 2013 | 15694 | 0.070 |
Why?
|
| RNA, Catalytic | 1 | 2006 | 37 | 0.070 |
Why?
|
| Dental Plaque | 1 | 2006 | 9 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 4892 | 0.070 |
Why?
|
| Risk Factors | 6 | 2024 | 17523 | 0.070 |
Why?
|
| Melanoma, Experimental | 2 | 2019 | 368 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2021 | 3518 | 0.070 |
Why?
|
| Alzheimer Disease | 1 | 2013 | 855 | 0.070 |
Why?
|
| Endometrium | 2 | 2020 | 470 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 1491 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2024 | 2054 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 5539 | 0.060 |
Why?
|
| Genotype | 1 | 2013 | 4109 | 0.060 |
Why?
|
| Genomics | 1 | 2016 | 2738 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2006 | 185 | 0.060 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 2265 | 0.060 |
Why?
|
| Mammography | 1 | 2011 | 1010 | 0.060 |
Why?
|
| Genome, Human | 1 | 2013 | 1869 | 0.060 |
Why?
|
| Mutation | 4 | 2022 | 15179 | 0.060 |
Why?
|
| Data Collection | 1 | 2007 | 620 | 0.060 |
Why?
|
| Adolescent | 9 | 2017 | 31252 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 460 | 0.060 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 4314 | 0.060 |
Why?
|
| Body Mass Index | 3 | 2020 | 2203 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 1879 | 0.060 |
Why?
|
| Esophageal Neoplasms | 1 | 2018 | 3168 | 0.060 |
Why?
|
| Transcriptome | 1 | 2012 | 1859 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 2314 | 0.060 |
Why?
|
| Doxorubicin | 2 | 2012 | 3005 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 1429 | 0.060 |
Why?
|
| CD47 Antigen | 1 | 2022 | 26 | 0.060 |
Why?
|
| Disease Progression | 1 | 2014 | 6682 | 0.050 |
Why?
|
| Retrospective Studies | 7 | 2024 | 37905 | 0.050 |
Why?
|
| Melanoma | 1 | 2019 | 5317 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 4988 | 0.050 |
Why?
|
| Fatigue | 2 | 2022 | 1239 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2021 | 2292 | 0.050 |
Why?
|
| Headache | 1 | 2022 | 163 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2024 | 571 | 0.050 |
Why?
|
| Mesocricetus | 1 | 2021 | 114 | 0.050 |
Why?
|
| Pyridines | 2 | 2022 | 1244 | 0.050 |
Why?
|
| Surveys and Questionnaires | 4 | 2017 | 5687 | 0.050 |
Why?
|
| Lymphoma | 1 | 2009 | 1467 | 0.050 |
Why?
|
| Transfection | 1 | 2006 | 2944 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2022 | 354 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 1547 | 0.050 |
Why?
|
| Microsatellite Repeats | 2 | 2017 | 575 | 0.050 |
Why?
|
| Communication | 2 | 2021 | 876 | 0.050 |
Why?
|
| Cricetinae | 1 | 2021 | 706 | 0.050 |
Why?
|
| Cyclin E | 1 | 2022 | 267 | 0.050 |
Why?
|
| Dacarbazine | 2 | 2013 | 485 | 0.050 |
Why?
|
| Retinal Dehydrogenase | 1 | 2020 | 91 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2024 | 842 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2024 | 938 | 0.050 |
Why?
|
| Polymers | 1 | 2021 | 223 | 0.050 |
Why?
|
| Diarrhea | 1 | 2024 | 686 | 0.050 |
Why?
|
| Anilides | 1 | 2022 | 268 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2022 | 341 | 0.050 |
Why?
|
| Mice | 6 | 2019 | 34495 | 0.040 |
Why?
|
| Receptor, EphA2 | 1 | 2021 | 132 | 0.040 |
Why?
|
| Caveolin 1 | 1 | 2021 | 204 | 0.040 |
Why?
|
| Conflict of Interest | 1 | 2020 | 98 | 0.040 |
Why?
|
| Phthalazines | 1 | 2021 | 253 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2017 | 1586 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2021 | 429 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 3552 | 0.040 |
Why?
|
| Quinazolines | 1 | 2024 | 923 | 0.040 |
Why?
|
| Rats | 2 | 2021 | 6086 | 0.040 |
Why?
|
| Students | 1 | 2021 | 324 | 0.040 |
Why?
|
| Survival Rate | 3 | 2021 | 12221 | 0.040 |
Why?
|
| Receptors, Progesterone | 2 | 2015 | 1392 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 992 | 0.040 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 10331 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2020 | 666 | 0.040 |
Why?
|
| Health Status | 1 | 2021 | 590 | 0.040 |
Why?
|
| Texas | 2 | 2019 | 6311 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 7551 | 0.040 |
Why?
|
| Virus Replication | 1 | 2021 | 709 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2018 | 115 | 0.040 |
Why?
|
| Universities | 1 | 2019 | 160 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2018 | 158 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 8865 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 2588 | 0.040 |
Why?
|
| Carboplatin | 1 | 2021 | 823 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 430 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2018 | 7226 | 0.040 |
Why?
|
| OX40 Ligand | 1 | 2017 | 28 | 0.040 |
Why?
|
| Pyrroles | 1 | 2021 | 576 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2015 | 9180 | 0.040 |
Why?
|
| Dasatinib | 1 | 2021 | 862 | 0.040 |
Why?
|
| A549 Cells | 1 | 2017 | 124 | 0.040 |
Why?
|
| Michigan | 2 | 2007 | 67 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2024 | 1546 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 650 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 1146 | 0.040 |
Why?
|
| Uterus | 1 | 2021 | 678 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2020 | 862 | 0.040 |
Why?
|
| Sex Factors | 2 | 2012 | 2139 | 0.040 |
Why?
|
| Family Relations | 1 | 2017 | 88 | 0.040 |
Why?
|
| Adiposity | 1 | 2018 | 237 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 582 | 0.030 |
Why?
|
| Patient Satisfaction | 2 | 2012 | 915 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2021 | 1459 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 672 | 0.030 |
Why?
|
| Protein Binding | 1 | 2022 | 3438 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 1742 | 0.030 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2015 | 89 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2022 | 1756 | 0.030 |
Why?
|
| Body Composition | 1 | 2018 | 595 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2019 | 1681 | 0.030 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2015 | 113 | 0.030 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2015 | 160 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2017 | 380 | 0.030 |
Why?
|
| Perception | 1 | 2017 | 350 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2022 | 1248 | 0.030 |
Why?
|
| Radiotherapy | 2 | 2013 | 1824 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2015 | 245 | 0.030 |
Why?
|
| Normal Distribution | 1 | 2014 | 61 | 0.030 |
Why?
|
| Web Browser | 1 | 2013 | 17 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 1183 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2021 | 1996 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 1439 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2022 | 2045 | 0.030 |
Why?
|
| Weight Loss | 1 | 2018 | 627 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 1304 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2015 | 327 | 0.030 |
Why?
|
| Oligodendrocyte Transcription Factor 2 | 1 | 2013 | 25 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 342 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2018 | 12873 | 0.030 |
Why?
|
| Expert Testimony | 1 | 2014 | 90 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2017 | 518 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2017 | 1489 | 0.030 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2014 | 226 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2017 | 731 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 2014 | 210 | 0.030 |
Why?
|
| Piperazines | 1 | 2021 | 2101 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 671 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2014 | 4078 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 748 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 3570 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2013 | 198 | 0.030 |
Why?
|
| Protein Stability | 1 | 2013 | 370 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 2216 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2013 | 497 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1987 | 0.030 |
Why?
|
| beta Catenin | 1 | 2015 | 688 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2013 | 249 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2014 | 402 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 1648 | 0.020 |
Why?
|
| Alopecia | 1 | 2012 | 126 | 0.020 |
Why?
|
| Vinblastine | 1 | 2012 | 453 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 701 | 0.020 |
Why?
|
| Bleomycin | 1 | 2012 | 467 | 0.020 |
Why?
|
| Speech | 1 | 2012 | 133 | 0.020 |
Why?
|
| Cell Movement | 1 | 2018 | 2466 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 1005 | 0.020 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 1022 | 0.020 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2009 | 6 | 0.020 |
Why?
|
| Ejaculation | 1 | 2009 | 24 | 0.020 |
Why?
|
| Norway | 1 | 2009 | 30 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 3981 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2011 | 875 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2009 | 40 | 0.020 |
Why?
|
| Biopsy | 1 | 2018 | 3443 | 0.020 |
Why?
|
| Self Report | 1 | 2013 | 756 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2020 | 2819 | 0.020 |
Why?
|
| Eating | 1 | 2012 | 421 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 14889 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 2173 | 0.020 |
Why?
|
| Penile Erection | 1 | 2009 | 86 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2009 | 165 | 0.020 |
Why?
|
| Aftercare | 1 | 2011 | 259 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 1165 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 8873 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 1062 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 864 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2011 | 6150 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2009 | 140 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2015 | 1026 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 703 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 4844 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2008 | 30 | 0.020 |
Why?
|
| DMF Index | 1 | 2007 | 3 | 0.020 |
Why?
|
| Tooth, Deciduous | 1 | 2007 | 6 | 0.020 |
Why?
|
| Cytokines | 1 | 2017 | 2809 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 4975 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 698 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1217 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 3101 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 5112 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 9244 | 0.020 |
Why?
|
| Piperidines | 1 | 2013 | 1035 | 0.020 |
Why?
|
| Neutropenia | 1 | 2012 | 968 | 0.020 |
Why?
|
| Beverages | 1 | 2007 | 105 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 3890 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 589 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2018 | 2967 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 356 | 0.020 |
Why?
|
| Health Promotion | 1 | 2011 | 502 | 0.020 |
Why?
|
| Rituximab | 1 | 2012 | 1528 | 0.020 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2007 | 174 | 0.020 |
Why?
|
| Short Interspersed Nucleotide Elements | 1 | 2006 | 27 | 0.020 |
Why?
|
| Base Composition | 1 | 2006 | 92 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7222 | 0.020 |
Why?
|
| Hypogonadism | 1 | 2009 | 257 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2006 | 101 | 0.020 |
Why?
|
| Synteny | 1 | 2006 | 87 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2012 | 717 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 6942 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 2508 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 2084 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 2086 | 0.020 |
Why?
|
| Biological Availability | 1 | 2006 | 214 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 3569 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2006 | 336 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 3536 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2006 | 204 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2006 | 218 | 0.020 |
Why?
|
| Genes | 1 | 2006 | 491 | 0.020 |
Why?
|
| Testosterone | 1 | 2009 | 619 | 0.020 |
Why?
|
| Pan troglodytes | 1 | 2006 | 207 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 306 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2011 | 1863 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 5395 | 0.020 |
Why?
|
| Poverty | 1 | 2007 | 471 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2008 | 613 | 0.010 |
Why?
|
| CpG Islands | 1 | 2006 | 633 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2013 | 2518 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2006 | 875 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2008 | 1081 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2006 | 834 | 0.010 |
Why?
|
| Age Factors | 1 | 2011 | 5377 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 1225 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 1533 | 0.010 |
Why?
|
| Pregnancy | 1 | 2014 | 7573 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 3045 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 6089 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 2483 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 7548 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2007 | 16273 | 0.010 |
Why?
|